Borosil Scientific Ltd
Since 1962, Borosil is into finest quality scientific and laboratory glassware, which is used in Quality Control in pharmaceutical industries, Food and Soil testing, Microbiology, and Biotechnology.[1]
- Market Cap ₹ 946 Cr.
- Current Price ₹ 106
- High / Low ₹ 181 / 96.6
- Stock P/E 20.5
- Book Value ₹ 53.5
- Dividend Yield 0.00 %
- ROCE 14.2 %
- ROE 10.5 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 123 days to 92.1 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 9.34% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Industrials Capital Goods Industrial Products Glass - Industrial
Part of BSE Industrials
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| 323 | 353 | 389 | 424 | 443 | |
| Sales growth | +9% | +10% | +9% | +11% | |
| 272 | 301 | 330 | 353 | 372 | |
| Operating Profit | 51 | 53 | 58 | 71 | 71 |
| OPM % | 16% | 15% | 15% | 17% | 16% |
| 5 | 4 | 8 | 1 | 8 | |
| Interest | 1 | 1 | 1 | 0 | 0 |
| Depreciation | 12 | 15 | 17 | 18 | 18 |
| Profit before tax | 43 | 40 | 48 | 54 | 61 |
| Tax % | 29% | 21% | 28% | 26% | |
| 30 | 31 | 35 | 40 | 45 | |
| EPS in Rs | 3.54 | 3.94 | 4.47 | 5.04 | |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 10% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| TTM: | 31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 9% |
| Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.29 | 9 | 9 | 9 | 9 |
| Reserves | 352 | 374 | 411 | 453 | 467 |
| 11 | 11 | 6 | 1 | 1 | |
| 69 | 82 | 74 | 87 | 82 | |
| Total Liabilities | 432 | 477 | 499 | 549 | 558 |
| 150 | 159 | 155 | 156 | 168 | |
| CWIP | 8 | 1 | 1 | 9 | 1 |
| Investments | 32 | 41 | 146 | 175 | 175 |
| 241 | 275 | 197 | 209 | 214 | |
| Total Assets | 432 | 477 | 499 | 549 | 558 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| -57 | 32 | 127 | 50 | |
| 50 | -20 | -121 | -47 | |
| 7 | -1 | -5 | -4 | |
| Net Cash Flow | 0 | 11 | 1 | -1 |
| Free Cash Flow | -85 | 20 | 114 | 25 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -97% | 94% | 237% | 92% |
Ratios
Standalone / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 46 | 54 | 60 | 62 |
| Inventory Days | 325 | 256 | 227 | 232 |
| Days Payable | 70 | 102 | 79 | 98 |
| Cash Conversion Cycle | 301 | 208 | 207 | 196 |
| Working Capital Days | 190 | 181 | 96 | 92 |
| ROCE % | 11% | 12% | 14% |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Laboratory glassware manufacturing capacity (Bharuch) units/day |
|
||
| Number of channel partners partners |
|||
| Number of exporting countries countries |
|||
| Number of SKUs SKUs |
|||
| Glass Ampoules manufacturing capacity Mn p.a. |
|||
| Market share in domestic laboratory glassware % |
|||
| Pharmaceutical share of scientific customer mix % |
|||
| Tubular Glass Vials manufacturing capacity Mn p.a. |
|||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor Presentation for the quarter & half year ended September 30, 2026
- Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended September 30, 2026
-
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
- Board approved up to Rs. 70 crore glass tubing furnace at Bharuch; production expected by March 31, 2028.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On October 28, 2026
- Board approved Q2 FY26 results and Rs70 crore glass tubing furnace at Bharuch, targeting March 2028 production.
-
Board Meeting Intimation for Approval Of The Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended September 30, 2026
- Board meets on October 28, 2026 to approve Q2 and half-year FY27 unaudited results.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
Borosil Group[1]
The company is a part of Borosil group which is into glassware and laboratory products,
scientific & industrial glassware, consumer & kitchenware products, and solar glass products. Group comprises of:
1. Borosil Renewables Ltd
2. Borosil Ltd
3. Borosil Scientific Ltd